Clincosm LogoSign in Get a demo

Non-small Cell Lung Carcinoma

Showing 1 - 25 of 47
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Non-Small Cell Lung Carcinoma, NSCLC Trial run by the National Cancer Institute (NCI) (biological, drug, device)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Montanide (Registered Trademark) ISA-51 VG Adjuvant
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, NSCLC Trial (JDQ443, trametinib, Ribociclib)

Recruiting
  • KRAS G12C Mutant Solid Tumors
  • +10 more
  • Boston, Massachusetts
  • +5 more
Jan 11, 2023

Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)

Recruiting
  • Non-Small Cell Lung Carcinoma
  • Capmatinib 150 mg
  • Capmatinib 200 mg
  • Guwahati, Assam, India
  • +7 more
Dec 19, 2022

Breast Cancer, Non-small Cell Lung Carcinoma Trial in Worldwide (Trastuzumab deruxtecan (DS-8201a), Pembrolizumab)

Recruiting
  • Breast Cancer
  • Non-small Cell Lung Carcinoma
  • San Francisco, California
  • +24 more
Nov 30, 2022

Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)

Completed
  • Melanoma
  • +27 more
  • XmAb20717
  • Los Angeles, California
  • +16 more
Nov 29, 2022

Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or

Active, not recruiting
  • Melanoma
  • +8 more
  • Los Angeles, California
  • +9 more
Nov 15, 2022

Non-small Cell Lung Carcinoma Trial (Pembrolizumab, Paclitaxel, Carboplatin)

Completed
Has Results
  • Non-small Cell Lung Carcinoma
  • Pembrolizumab
  • +7 more
  • (no location specified)
Oct 13, 2022

Non-small Cell Lung Carcinoma Trial (BPI-361175)

Not yet recruiting
  • Non-small Cell Lung Carcinoma
  • (no location specified)
Oct 18, 2022

Observing Palliative Asymptomatic Centrally Located Advanced

Active, not recruiting
  • Non-small Cell Lung Carcinoma
  • None: Questionnaire Study
  • Toronto, Ontario, Canada
    University Health Network, Princess Margaret Hospital
Oct 6, 2022

Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon Trial in United States (afatinib,

Completed
  • Non-small Cell Lung Carcinoma
  • +3 more
  • Denver, Colorado
  • +7 more
Aug 17, 2022

Malignant Lung Tumor, Metastatic Malignant Tumor in the Lung, Non-Small Cell Lung Carcinoma Trial in Palo Alto (device, drug,

Active, not recruiting
  • Malignant Lung Neoplasm
  • +3 more
  • CAPP-Seq
  • +2 more
  • Palo Alto, California
    Stanford University, School of Medicine
May 31, 2022

NSCLC, NSCLC, Non-Small Cell Lung Carcinoma Trial in United States (efineptakin alfa, Atezolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +4 more
  • Mobile, Alabama
  • +14 more
May 12, 2022

Non-Small Cell Lung Carcinoma Trial in Duarte, Stanford, Nashville (drug, biological, other)

Terminated
  • Non-Small Cell Lung Carcinoma
  • Duarte, California
  • +2 more
Apr 6, 2022

Non-Small Cell Lung Carcinoma, Compliance Behavior, Prevention Harmful Effects Trial in Dallas (Patient Navigation)

Active, not recruiting
  • Non-Small Cell Lung Carcinoma
  • +2 more
  • Patient Navigation
  • Dallas, Texas
    Simmons Comprehensive Cancer Center at University of Texas South
Mar 30, 2022

Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma, Small Cell Lung Carcinoma Trial in Buffalo (Porfimer Sodium,

Recruiting
  • Locally Advanced Lung Carcinoma
  • +6 more
  • Porfimer Sodium
  • Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy
  • Buffalo, New York
    Roswell Park Cancer Institute
Mar 14, 2022

Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC Trial in Worldwide (TNO155, Spartalizumab,

Recruiting
  • Non-small Cell Lung Carcinoma
  • +4 more
  • Boston, Massachusetts
  • +8 more
Mar 18, 2022

Adult Solid Tumor, Bladder Carcinoma, Colon Carcinoma Trial in Duarte (Laboratory Biomarker Analysis, Modified Vaccinia Virus

Active, not recruiting
  • Adult Solid Neoplasm
  • +16 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Mar 17, 2022

Non-small Cell Lung Carcinoma Trial in China (Almonertinib, Pemetrexed, Cisplatin)

Enrolling by invitation
  • Non-small Cell Lung Carcinoma
  • Beijing, Beijing, China
  • +33 more
Feb 8, 2022

Non-small Cell Lung Carcinoma Trial in Rochester, Lebanon, Durham (Pembrolizumab)

Active, not recruiting
Has Results
  • Non-small Cell Lung Carcinoma
  • Rochester, Minnesota
  • +2 more
Feb 17, 2022

Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma Trial in Boston, Newton (Contralateral Esophageal Sparing Technique

Completed
Has Results
  • Non-small Cell Lung Carcinoma
  • Small Cell Lung Carcinoma
  • Contralateral Esophageal Sparing Technique (CEST)
  • Boston, Massachusetts
  • +1 more
Dec 8, 2021

Solid Tumors, Non-small Cell Lung Carcinoma Trial in United States (DS-2248)

Terminated
Has Results
  • Solid Tumors
  • Non-small Cell Lung Carcinoma
  • Duarte, California
  • +8 more
Sep 9, 2021

Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma Trial in United States (XmAb®23104, Yervoy®

Recruiting
  • Melanoma (Excluding Uveal Melanoma)
  • +15 more
  • XmAb®23104
  • Yervoy® (ipilimumab)
  • San Diego, California
  • +15 more
Sep 20, 2021

Non-small Cell Lung Carcinoma Trial (Drug: Furmonertinib 80 mg, Furmonertinib 80 mg )

Not yet recruiting
  • Non-small Cell Lung Carcinoma
  • Drug: Furmonertinib 80 mg
  • Furmonertinib 80 mg placebo
  • (no location specified)
Apr 19, 2021

Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma Trial in United States (SGN-CD47M)

Terminated
  • Soft Tissue Sarcoma
  • +8 more
  • Cleveland, Ohio
  • +4 more
Sep 15, 2020

Cancer of the Lung, Lung Cancer, Tumors, Lung Trial in United States (Microwave ablation)

Withdrawn
  • Cancer of the Lung
  • +5 more
  • Microwave ablation
  • Duarte, California
  • +4 more
May 29, 2020